In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Germany’s Pricing Revolution: Why The World Should Be Watching

Executive Summary

Germany’s new early-benefit assessment system for all new drugs launched since Jan. 1, 2011, radically changes the status of Europe’s largest market. It was once a bastion of free (and thus relatively high) pricing, which firms used to signal their drugs’ value to other markets. Now, prices of new drugs will be negotiated between sponsors and the country’s association of statutory sick funds, on the basis of an added-benefit score determined by the G-BA, or Federal Joint Committee. Since those net prices will be made public, and many other countries reference German prices, there’s a real risk of a downward price spiral across Europe.

You may also be interested in...

Almirall May Pull Sativex After German Arbitration Board Pricing Decision

Germany’s reimbursement arbitration board has proposed a rock bottom price for GW Pharmaceuticals/Almirall’s cannabinoid preparation Sativex (nabiximols) for MS-related spasticity.

GSK’s Benlysta Discount Isn’t Big Enough To Avoid NICE Rejection

NICE says GSK did not adequately compare its lupus drug belimumab to Roche’s Mab Thera (rituximab). While the firm and partner Human Genome Sciences did offer data that appeared to show an advantage, the problem is that the positive results were more prevalent in a patient population that did not broadly reflect the make-up of the U.K., NICE said.

German Parallel Importers Threaten Action Against Pharma Price Secrecy

Parallel traders of pharmaceuticals in Germany say that hiding the final price of products after negotiations between insurers and manufacturers could destroy their livelihood and is possibly illegal.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts